SPL7013 outperformed Gilead against COVID-19, page-30

First 30 Last

Share
Profile

Follow
antibotter

12,901 Posts.

1439

02/05/20

16:46

Post #: 44398324
Share

Originally posted by stoway ↑

https://news.yahoo.com/fda-allows-emergency-drug-coronavirus-195025339.html

"The FDA said preliminary results from the government study warranted Friday's decision, though regulators acknowledged “there is limited information known about the safety and effectiveness of using remdesivir.”The drug's side effects include potential inflammation of the liver and problems related to its infusion, which could lead to nausea, vomiting, sweating and low blood pressure. Information about dosing and potential safety issues will be provided to physicians and patients, the FDA said.The National Institutes of Health’s Dr. Anthony Fauci said Wednesday the drug would become a new standard of care for severely ill COVID-19 patients. Remdesivir, which blocks an enzyme the virus uses to copy its genetic material, has not been tested on people with milder illness.The FDA authorized the drug under its emergency powers to quickly speed the availability of experimental drugs, tests and other medical products during public health crises.In normal times the FDA requires “substantial evidence” of a drug’s safety and effectiveness, usually through one or more large, rigorously controlled patient studies. But during public health emergencies the agency can waive those standards and require only that an experimental treatment's potential benefits outweigh its risks.Gilead has said it will donate its currently available stock of the drug and is ramping up production to make more. It said the U.S. government would coordinate distribution of remdesivir to parts of the country that need it most."

Expand

Hmmm dangerous side effects

Sounds like a job for

DEP®Redesivir

would/could Gilead collaborate with Starpharma to develop a safer version using Starpharma's drug delivery platform (spl7013)

SPL Price at posting: $1.09 Sentiment: Buy Disclosure: Held
1 Upvote

1 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RXL

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 4 more messages in this thread...

First 30 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change 0.000(0.00%)		Mkt cap ! $40.48M

Open	High	Low	Value	Volume
9.9¢	9.9¢	9.7¢	$2.044K	21.06K

Buyers (Bids)

No.	Vol.	Price($)
2	60526	9.5¢

Sellers (Offers)

Price($)	Vol.	No.
9.6¢	61673	1

View Market Depth

No.	Vol.	Price($)
2	60526	0.095
1	10000	0.094
2	134306	0.092
3	81442	0.090
1	30000	0.089

Price($)	Vol.	No.
0.096	61673	1
0.097	107702	1
0.098	16000	1
0.100	38876	3
0.105	199768	2

Last trade - 10.31am 04/10/2024 (20 minute delay)

SPL (ASX) Chart

SPL7013 outperformed Gilead against COVID-19, page-30

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

SPL7013 outperformed Gilead against COVID-19, page-30

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News